Please make sure that you select the correct MabThera® (rituximab) formulation

SUBCUTANEOUS INJECTION

For use in non-Hodgkin's lymphoma ONLY†*

MabThera 1400 mg solution for subcutaneous injection

Withdraw directly from the vial and administer by subcutaneous injection

Check for the specific MabThera SC packaging characteristics before use:

1. Red labelling: '**For subcutaneous use only**', '**solution for subcutaneous injection**' and '**SC**'
2. Pink flip-off cap
3. Strength: '1,400mg /11.7mL

INTRAVENOUS INFUSION

For use in all MabThera-approved indications†

MabThera 100 mg concentrate for solution for infusion
MabThera 500 mg concentrate for solution for infusion



Dilute with 0.9% NaCl or 5% glucose and administer by intravenous infusion



Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Reporting forms and information can be found at www.medicinesauthority.gov.mt/adrportal and sent by email to postlicensing.medicinesauthority@gov.mt or posted to ADR Reporting, The Medicines Authority Post-licensing Directorate, 203, Level 3, Rue D'Argens, Gżira GŻR 1368, MALTA. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. As MabThera is a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.

*MabThera SC is not indicated as once-weekly monotherapy in patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.
†Please refer to the Summary of Product Characteristics for further information: www.medicines.org.uk

Published by Roche Products Limited

This educational material is provided by Roche Products Limited and is mandatory as a condition of the Marketing Authorisation in order to further minimise important selected risks.

RXUKMABO00690c
Date of preparation: April 2014